[Biological activity of enoxaprine (PK 10169) in hemodialysis. A dose study].
Anti-Xa and anti-IIa activity were evaluated in 42 patients with chronic renal insufficiency, in an open randomized trial, to determine optimal dose of PK 10169 for prevention of coagulation in extracorporeal circuit during hemodialysis sessions. PK 10169 was given as single doses of 0.75, 1 and 1.25 mg/kg at start of dialysis, into the arterial line. All dialysis sessions were continued over the 4 hours provided for without the need for further injections. A linear relation existed between anti-Xa and anti-IIa activity measured at end of dialysis and the dose injected (p less than 0.001). Efficacy and tolerance were assessed clinically and biologically and were rated excellent at the 3 dose levels, the best tolerance/efficacy ratio being at the 1 mg/kg dosage.
Pouzol
P
P
Laboratoire d'Hématologie, C.H.U., Grenoble.
Polack
B
B
Dechelette
E
E
Jurkovitz
C
C
Cusin
E
E
D000328:Adult; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005170:Factor X / Q000032:analysis / Q000037:antagonists & inhibitors; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011516:Prothrombin / Q000032:analysis / Q000037:antagonists & inhibitors; D011897:Random Allocation; D006435:Renal Dialysis
D006495:Heparin, Low-Molecular-Weight; D011516:Prothrombin; D005170:Factor X; C025337:Factor IIa
Activités biologiques de l'éjnoxaparine (PK 10,169) en hémodialyse. Etude de dose.